Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat

Molecular and Cellular Endocrinology

Volumn 328, Issue 1-2, 2010, Pages 16-21

  Attardi, Barbara J ^a   Koduri, Sailaja ^a   Hild, Sheri A ^a  

^a BIOQUAL INC   (United States)

Author keywords

Castrate male rats; LH suppression; Male contraception; Progestins; Steroid receptor binding; Transactivation

Indexed keywords

ANDROGEN RECEPTOR; CYPROTERONE ACETATE; ELCOMETRINE; GESTAGEN; LEVONORGESTREL; LUTEINIZING HORMONE; METRIBOLONE; NORETHISTERONE ACETATE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; STEROID RECEPTOR; TESTOSTERONE;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BLOOD SAMPLING; CANCER CELL CULTURE; CASTRATION; CONTRACEPTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TRANSACTIVATION;

ANDROGENS; ANIMALS; CONTRACEPTION; CONTRACEPTIVE AGENTS, MALE; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; LUCIFERASES; LUTEINIZING HORMONE; MALE; ORCHIECTOMY; PROGESTINS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 77956394541     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.06.010     Document Type: Article

References (21)

1. Attardi B.J., Reel J.R., Hild S.A., Burgenson J., Blye.R.P. CDB-4124 and its putative metabolite CDB-4453 are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol. Cell. Endocrinol. 2002, 188:111-123.
2. Attardi B.J., Burgenson J., Hild S.A., Reel J.R. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol. Cell. Endocrinol. 2004, 222:121-132.
3. Attardi B.J., Hild S.A., Reel J.R. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology 2006, 147:3016-3026.
4. Attardi B., Engbring J.A., Gropp D., Koduri S., Hild S.A. Potent orally active synthetic androgens, dimethandrolone undecanoate (DMAU: 7α,11β-dimethyl-19-nortestosterone 17β-undecanoate) and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate (11β-MNTDC) as potential single agent male contraceptives: testing in an adult male rabbit model. 9th International Congress of Andrology 2009, (abstract).
5. Bovee T.F., Helsdingen R.J., Hamers A.R., van Duursen M.B., Nielen M.W., Hoogenboom R.L. A new highly specific and robust yeast androgen bioassay for the detection of agonists and antagonists. Anal. Bioanal. Chem. 2007, 389:1549-1558.
6. Elger W., Beier S., Pollow K., Garfield R., Shi S.Q., Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003, 68:891-905.
7. Gao W., Bohl C.E., Dalton J.T. Chemistry and structural biology of androgen receptor. Chem. Rev. 2005, 105:3352-3370.
8. Herbst K.L., Anawalt B.D., Amory J.K., Matsumoto A.M., Bremner W.J. The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4 weeks, but attenuates a decrease in fat mass induced by testosterone alone. J. Clin. Endocrinol. Metab. 2003, 88:1167-1173.
9. Hild S.A., Engbring J.A., Attardi B.J., Gropp D., Koduri S., Reel J.R. Development of dimethandrolone 17β-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. Society for the Study of Reproduction 2008, (abstract 174).
10. Horwitz K.B., Mockus M.B., Lessey B.A. Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 1982, 28:633-642.
11. Kumar N., Koide S.S., Tsong Y.-Y., Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000, 5:629-636.
12. Liu P.Y., Swerdloff R.S., Anawalt B.D., Anderson R.A., Bremner W.J., Elliesen J., Gu Y.Q., Kersemaekers W.M., McLachlan R.I., Meriggiola M.C., Nieschlag E., Sitruk-Ware R., Vogelsong K., Wang X.H., Wu F.C., Zitzmann M., Handelsman D.J., Wang C. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J. Clin. Endocrinol. Metab. 2008, 93:1774-1783.
13. Mahabadi V., Amory J.K., Swerdloff R.S., Bremner W.J., Page S.T., Sitruk-Ware R., Christensen P.D., Kumar N., Tsong Y.-Y., Blithe D., Wang C. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J. Clin. Endocrinol. Metab. 2009, 94:2313-2320.
14. McRobb L., Handelsman D.J., Kazlauskas R., Wilkinson S., McLeod M.D., Heather A.K. Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay. J. Steroid Biochem. Mol. Biol. 2008, 110:39-47.
15. McPhail M.K. The assay of progestin. J. Physiol. (Lond) 1934, 83:145-156.
16. Nieschlag E., Zitzmann M., Kamischke A. Use of progestins in male contraception. Steroids 2003, 68:965-972.
17. Page S.T., Amory J.K., Bremner W.J. Advances in male contraception. Endocr. Rev. 2008, 29:465-493.
18. Roy P., Alevizaki M., Huhtaniemi I. In vitro bioassays for androgens and their diagnostic applications. Hum. Reprod. Update 2008, 14:73-82.
19. Sitruk-Ware R. New progestagens for contraceptive use. Hum. Reprod. Update 2006, 12:169-178.
20. Sonneveld E., Riteco J.A., Jansen H.J., Pieterse B., Brouwer A., Schoonen W.G., van der Burg B. Comparison of in vitro and in vivo screening models for androgenic and estrogenic potencies. Toxicol. Sci. 2006, 89:173-187.
21. Zitzmann M., Sitruk-Ware R., Nieschlag E. Progestin effects on gonadotropin levels. Program of the Future of Male Contraception 2007, (abstract).